Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. Jama. 2005, 294: 238-244. 10.1001/jama.294.2.238.
Article
CAS
PubMed
Google Scholar
Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002, 360: 103-106. 10.1016/S0140-6736(02)09408-4.
Article
CAS
PubMed
Google Scholar
Bolla M, van Tienhoven G, de Reijke TM, van den Bergh AC, van der Meijden AP, Poortmans PM, Gez E, Kil P, Pierart M, Collette L, Groups EROaG-UT: Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961. J Clin Oncol (Meeting Abstracts). 2007, 25: 5014--
Google Scholar
D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW: Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Jama. 2008, 299: 289-295.
PubMed
Google Scholar
D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. Jama. 2004, 292: 821-827.
Article
PubMed
Google Scholar
Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005, 6: 841-850. 10.1016/S1470-2045(05)70348-X.
Article
CAS
PubMed
Google Scholar
Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F: The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004, 171: 1137-1140. 10.1097/01.ju.0000112979.97941.7f.
Article
CAS
PubMed
Google Scholar
Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001, 50: 1243-1252. 10.1016/S0360-3016(01)01579-6.
Article
CAS
PubMed
Google Scholar
Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005, 61: 1285-1290. 10.1016/j.ijrobp.2004.08.047.
Article
CAS
PubMed
Google Scholar
Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008, 26: 585-591. 10.1200/JCO.2007.13.9881.
Article
PubMed
Google Scholar
See WA, Tyrrell CJ: The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 2006, 132 (Suppl 1): S7-16. 10.1007/s00432-006-0132-6.
Article
CAS
PubMed
Google Scholar
Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnaro P, Terzoli E, Cognetti F, Carlini P: Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer. 2009, 115: 3446-3456. 10.1002/cncr.24392.
Article
PubMed
Google Scholar
Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J: Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000, 47: 617-627. 10.1016/S0360-3016(00)00577-0.
Article
Google Scholar
Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006, 24: 3979-3983. 10.1200/JCO.2006.05.9741.
Article
PubMed
Google Scholar
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005, 352: 154-164. 10.1056/NEJMoa041943.
Article
CAS
PubMed
Google Scholar
Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, et al: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 8: 162-200.
Mohler JL: The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 8: 145-
Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol. 1996, 156: 873-877. 10.1016/S0022-5347(01)65645-3.
Article
CAS
PubMed
Google Scholar
Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995, 154: 424-428. 10.1016/S0022-5347(01)67067-8.
Article
CAS
PubMed
Google Scholar
Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2001, 2: 475-482. 10.1016/S1470-2045(01)00453-3.
Article
CAS
PubMed
Google Scholar
Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nistico C, Terzoli E, Cognetti F, Giannarelli D: Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?: a meta-analysis of 20 phase 3 trials. Cancer. 2007, 110: 525-533. 10.1002/cncr.22809.
Article
PubMed
Google Scholar
Higgins JPT, Green S: Cochrane handbook for Systematic Reviews of intervention 4.2.6 [updated sep 2006]. The Cochrane Library. 2006, Chichester, UK: John Wiley & Sons, Ltd, 4
Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R: Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002, 7: 181-187. 10.1634/theoncologist.7-3-181.
Article
PubMed
Google Scholar
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Introduction to Meta-Analysis. 2009, Chichester, West Sussex, UK: John Wiley & Sons, Ltd. Publication
Book
Google Scholar
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.
Article
CAS
PubMed
Google Scholar
Shuster JJ: Empirical vs natural weighting in random effects meta-analysis. Stat Med. 29: 1259-1265. 10.1002/sim.3607.
Cochran WG: The combination of estimates from different experiments. Biometrics. 1954, 10: 101-129. 10.2307/3001666.
Article
Google Scholar
Deeks JJ: Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002, 21: 1575-1600. 10.1002/sim.1188.
Article
PubMed
Google Scholar
Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J: Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods. 2006, 11: 193-206. 10.1037/1082-989X.11.2.193.
Article
PubMed
Google Scholar
Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E, Cognetti F, Giannarelli D: Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer. 2009, 63: 50-57. 10.1016/j.lungcan.2008.05.002.
Article
PubMed
Google Scholar
Parmar MKB, Machin D: Survival analysis: a practical approach. 1995, Chichester (England): John Wiley
Google Scholar
Altman DG: Confidence intervals for the number needed to treat. Bmj. 1998, 317: 1309-1312.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bolla M, Collette L, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff ROM, Storme G, Bernier J, Kuten A, Piérart M: Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC Study. International Journal of Radiation Oncology & Biology & Physics, American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting September 1st, 2008; Boston. Edited by: Elsevier. 2008, S30-S31.
Google Scholar
Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009, 360: 2516-2527. 10.1056/NEJMoa0810095.
Article
CAS
PubMed
Google Scholar
Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G: Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004, 60: 15-23. 10.1016/j.ijrobp.2004.02.022.
Article
PubMed
Google Scholar
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU: Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008, 26: 2497-2504. 10.1200/JCO.2007.14.9021.
Article
CAS
PubMed
Google Scholar
Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME, Taylor JC, O'Shea CM, Buckney SJ, Thirion PG: A Randomized Trial (Irish Clinical Oncology Research Group 97-01) Comparing Short Versus Protracted Neoadjuvant Hormonal Therapy Before Radiotherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys.
Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnaro P, Terzoli E, Cognetti F, Carlini P: Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-Analysis of Randomized Trials. Cancer. 2009
Google Scholar
Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G: Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009, 73: 327-333. 10.1016/j.ijrobp.2008.04.075.
Article
CAS
PubMed
Google Scholar
Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009, 302: 866-873. 10.1001/jama.2009.1137.
Article
CAS
PubMed
Google Scholar
Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, et al: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007, 8: 475-487. 10.1016/S1470-2045(07)70143-2.
Article
PubMed
Google Scholar
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008, 70: 67-74. 10.1016/j.ijrobp.2007.06.054.
Article
PubMed
Google Scholar
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002, 53: 1097-1105. 10.1016/S0360-3016(02)02829-8.
Article
PubMed
Google Scholar
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005, 294: 1233-1239. 10.1001/jama.294.10.1233.
Article
CAS
PubMed
Google Scholar
Souhami L, Bae K, Pilepich M, Sandler H: Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol. 2009, 27: 2137-2143. 10.1200/JCO.2008.17.4052.
Article
PubMed
PubMed Central
Google Scholar
Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C: Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3-versus 8-month randomized trial. Int J Radiat Oncol Biol Phys. 76: 23-30.